Scheuermann’s disease: a case report

Scheuermann hastalığı spinal ağrı, kozmetik deformite, torakal disk hernisi ve prematür dejeneratif değişikliklere neden olan, adolesan çağda % 5-8 sıklıkta karşılaşılabilen bir hastalıktır. Etyoloji bilinmemekte, ailesel yatkınlık ve muhtemel lokal bir osteokondrit üzerinde durulmaktadır. Yorgunluk, ağrı, lokal hassasiyet gibi semptomlar pubertede başlar. Hastaların çoğu deformite ve kifozlarının farkında olmayıp tanı sıklıkla rutin bir lateral grafi çekimi ile konur. En sık orta ve alt torasik vertebralar tutulur, başka bir laboratuvar tanısı yoktur. Tedavi hastanın yaşı ve deformitesine bağlıdır. Analjezikler, rehabilitasyon egzersiz programları, ileri olgularda gerekirse destek operasyonları (Milwauke brace veya Harrington enstrumanları) uygulanabilir. Klinik ve radyolojik olarak Scheuermann hastalığı tanısı almış bir olgu sunuldu.Scheuermann s disease is a common disorder of the adolescent (5-8 %) which may result in spinal pain and cosmetic deformity and predispose to thorasic disc herniation and premature degenerative changes. The aetiology is unknown but may include a familial predisposition and possibly local osteochondritis. Symptoms like fatigue, pain, local tenderness become at puberty. Many of the patients are unaware that they have a deformity or kyphosis and are diagnosed by routine lateral chest radiographs. The most affected spinal regions are the mid or lower thoracic vertebrae and there are no other laboratory findings. Therapy depends on the degree of the deformity and on the patient s age. Analgesics, rehabilitation exercises, operations for stabilisation with a Milwauke brace or Harrington instruments may be tried. We present a patient with Scheuermann s disease with its clinic and radiologic findings

Sticky Platelet Syndrome in Patients with Uninduced Venous Thrombosis

Abstract: Objective: Sticky platelet syndrome (SPS) is a common autosomal dominant inherited platelet disorder. SPS is characterized by platelet hyperreactivity and is associated with arterial and venous thrombosis. The aim of this study was to determine the role of SPS in patients with uninduced venous thrombosis. Material and Methods: The study included 28 patients (15 male and 13 female) with uninduced venous thrombosis. SPS was defined according to Mammen's aggregation method, which is described in detail elsewhere. Results: According to the defined ranges for platelet hyperreactivity, 3 (50%) patients, 2 (33%), and 1 (17%) (n =6 [21%]) with a confirmed diagnosis were classified as type II, I, and III SPS, respectively. In 1 patient SPS was the only hereditary abnormality noted. The other 5 patients carried other inherited coagulation defects, in addition to SPS. Conclusio

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R PMBL in the phase 1/2 open-label, multicenter CheckMate 436 study; we report safety and efficacy findings from the 3-year follow-up. Patients who were eligible were aged ≥15 years with R/R PMBL previously treated with either high-dose chemotherapy plus autologous hematopoietic cell transplantation (HCT) or ≥2 prior multiagent chemotherapies, and had Eastern Cooperative Oncology Group performance status scores of 0 to 1 and CD30 expression of ≥1%. Patients were treated with nivolumab 240 mg and BV 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR); secondary end points included complete response rate, duration of response, progression-free survival (PFS), and overall survival (OS). Safety was monitored throughout. At final database lock (30 March 2022), 29 patients had received nivolumab plus BV; median follow-up was 39.6 months. Investigator-assessed ORR was 73.3%; median time to response was 1.3 months (range, 1.1-4.8). Median PFS was 26.0 months; median OS was not reached. PFS and OS rates at 24 months were 55.5% (95% confidence interval [CI], 32.0-73.8) and 75.5% (95% CI, 55.4-87.5), respectively. The most frequently occurring grade 3/4 treatment-related adverse event was neutropenia. Consolidative HCT was received by 12 patients, with a 100-day complete response rate of 100.0%. This 3-year follow-up showed long-term efficacy for nivolumab plus BV in R/R PMBL, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT02581631

Inactivation of peroxidase and lipoxygenase in carrots, green beans, and green peas by combination of high hydrostatic pressure and mild heat treatment

The efficiency of high hydrostatic pressure (HHP) with the combination of mild heat treatment on peroxidase (POD) and lipoxygenase (LOX) inactivation in carrots, green beans, and green peas was investigated. In the first part of the study, the samples were pressurized under 250-450 MPa at 20-50 degrees C for 15-60 min. In the second part, two steps treatments were performed as water blanching at 40-70 degrees C for 15 and 30 min after pressurization at 250 MPa and 20 degrees C for 15-60 min. Carrot POD was decreased to 16% residual activity within the first 30 min at a treatment condition of 350 MPa and 20 degrees C and then it decreased to 9% at 60 min. When the carrots were water blanched at 50 degrees C for 30 min after HHP treatment of 250 MPa at 20 degrees C for 15 min, 13% residual POD activity was obtained. For green beans, the most effective results were obtained by two steps treatment and approximately 25% residual POD activity was obtained by water blanching at 50 degrees C for 15 min after pressurization at 250 MPa and 20 degrees C for 60 min. An effective inactivation of POD in green peas was not obtained. For carrots, LOX activity could not be measured due to very low LOX activity or the presence of strong antioxidants such as carotenoids. After pressurization at 250 MPa and 20 degrees C for 15 or 30 min, water blanching at 60 degrees C for 30 min provided 2-3% residual LOX activity in green beans. The treatment of 250 MPa for 30 min and then water blanching at 50 degrees C for 30 min provided 70% LOX inactivation in green peas

Sticky Platelet Syndrome in Patients with Uninduced Venous Thrombosis

OBJECTIVE: Sticky platelet syndrome (SPS) is a common autosomal dominant inherited platelet disorder. SPS is characterized by platelet hyperreactivity and is associated with arterial and venous thrombosis. The aim of this study was to determine the role of SPS in patients with uninduced venous thrombosis. METHODS: The study included 28 patients (15 male and 13 female) with uninduced venous thrombosis. SPS was defined according to Mammen’s aggregation method, which is described in detail elsewhere. RESULTS: According to the defined ranges for platelet hyperreactivity, 3 (50%) patients, 2 (33%), and 1 (17%) (n =6 [21%]) with a confirmed diagnosis were classified as type II, I, and III SPS, respectively. In 1 patient SPS was the only hereditary abnormality noted. The other 5 patients carried other inherited coagulation defects, in addition to SPS. CONCLUSION: The present findings indicate that the prevalence of SPS was 21% in the patients with uninduced venous thrombosis. We therefore suggest that SPS should be considered in the differential diagnosis of such cases

Primary Breast Lymphoma Treated With R-Chop Chemotherapy

Primary breast lymphoma is rare disease which is treated with surgery, radiotherapy and chemoterapy. There is little experience of rituximab treatment is in breast lymphoma. Here we pres-ent a case of primary breast lymhoma treated with rituximab and chemotherapy combination. A 58-year-old woman referred for left breast mass. Radiologic imaging showed a mass of 4 cm in diameter. Pathologic examination of excisional biopsy specimen revealed Diffuse Large B Cell Lymphoma with CD20 positivity. The patient was stage IE (Ann Arbor). Mastectomy, lumpectomy or axil-lary dissection were not performed. Six courses of R-CHOP (CHOP plus rituximab) chemotherapy and radiotherapy were given. The complete response was obtained. The patient has been followed for 36 months with no evidence of disease recurrence. This is one of the first cases treated with rituximab. She has been followed for more than 36 months without relapse

Febril Neutropenia Etiology In A Hematology Department

Aim: Chemotherapy-induced febrile neutropenia (FN) predisposes patients to life-threatening infections and typically requires hospitalization. Patients with profound neutropenia have increased risk of septicemia associated with significant morbidity. To provide the appropriate broad-spectrum antimicrobial cover, documentation of causative agents and their antimicrobial susceptibilities should be established in each hospital. Methods: The goal of the present study was to investigate the causative microorganisms in 27 febrile neutropenic patients between January 2006 and December 2007. Results: ln our hematology unit, among 122 febrile neutropenic episodes 57 isolates from cultures of febrile neutropenic patients, gram-negative bacteria was prevalent (45.6%). Among the gram-positives (%42.1% of isolates) coagulase-negative staphylococci (CNS) were the predominant bacteria (13/23) followed by Staphylococcus aureus (7/23). Escherichia coli (14/26) and Klebsiella spp. (7/26) were the most common species among 26 gram-negative bacteria. Conclusion: The most important issue in febrile neutropenia is still a mortal situation in immunocompromised patients. So documentation of the flora in each unit would help to decide appropriate empirical therapy which is life saving

The Diagnosis Of Non Hodgkin Lymphoma In An Epidermodysplasia Verruciformis Patient

Epidermodysplasia verruciformis is a rare, multifactorial disorder. The disease has genetic and immunologic components. Many patients have impaired cell-mediated immunity. Although squamous cell cancers may develop in EV patients, the association with other hematological or solid malignancies and EV is reported in a few studies. In this report, a case of EV with primary mediastinal large B-cell lymphoma is presented. A 20-year-old man with a five years history of red-brown macular lesions was admitted to our hospital. The skin biopsy revealed epidermodysplasia verruciformis. Persistent cough started during the hospitalization. On the chest X-ray, mediastinal enlargement was determined. Thoracic computed tomography demonstrated a mediastinal mass of 6 cm in diameter. Diffuse, large B-cell lymphoma was diagnosed. The chemotherapy (R-CHOP regiment) and involved field radiotherapy were administered. Complete response was achieved after the combined treatment modality. He is lymphoma- free for 18 months follow-up. Epidermodysplasia verruciformis is frequently seen in immunosuppressive patients and many accompany infections with type human papilloma virus subtypes such as 5 and 8. These human papilloma virus subtypes that have oncogenic properties may trigger lymphomagenesis. In addition, lymphomas are seen more frequently in immunosuppressive patients than healthy persons. We conclude that there may be a predisposition to lymphoma development in epidermodysplasia verruciformis patients